Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

WCLC 2025

Lung, Respiratory and Thoracic Cancer

FLAURA2: Frontline osimertinib plus chemotherapy significantly improves OS in EGFR-mutated advanced NSCLC

Lung, Respiratory and Thoracic Cancer

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Lung Cancer (Auckl)

Luo FX, Arter Z, Ou SI, Nagasaka M

doi: 10.2147/LCTT.S520833

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

Lung Cancer

Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K

doi: 10.1016/j.lungcan.2025.108447

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Lung, Respiratory and Thoracic Cancer

A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC

J Thorac Oncol

Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I

doi: 10.1016/j.jtho.2025.06.002

Lung, Respiratory and Thoracic CancerCOVID-19

Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy

Lung Cancer

Guijosa A, Rios-Garcia E, Dávila-Dupont D, Cruz-Rico G, Russo A, Cabrera Miranda LA, Cardona AF, Rolfo C, Arrieta O

doi: 10.1016/j.lungcan.2025.108722

Lung, Respiratory and Thoracic Cancer

Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma

Lung Cancer

Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, Miyakoshi J, Tateishi A, Igawa YS, Higashiyama RI, Mochizuki A, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamamoto R, Yamamoto N, Watanabe SI, Yatabe Y, Takahashi K, Kohno T, Ohe Y

doi: 10.1016/j.lungcan.2025.108494

Related content

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

FLAURA2: Frontline osimertinib plus chemotherapy significantly improves OS in EGFR-mutated advanced NSCLC

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC

Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy

Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma